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Abstract
IMPORTANCE—An observational study found an increased risk of febrile seizure on the day of 
or 1 day after vaccination (days 0–1) with trivalent inactivated influenza vaccine (TIV) in the 
2010–2011 season; risk was highest with simultaneous vaccination with TIV and 13-valent 
pneumococcal vaccine (PCV13) in children who were 6 to 23 months old. Text messaging is a 
novel method for surveillance of adverse events after immunization that has not been used for 
hypothesis-driven vaccine safety research.
OBJECTIVE—To prospectively evaluate whether children receiving TIV and PCV13 
simultaneously had higher rates of fever on days 0 to 1 than those receiving either product without 
the other.
DESIGN, SETTING, AND PARTICIPANTS—Prospective observational cohort study of parents 
of children 6 to 23 months old recruited from 3 medical center–affiliated clinics in New York City 
from November 1, 2011, through April 5, 2012. A total of 530 of 614 eligible participants (86.3%) 
were enrolled. Parents were texted on the night of vaccination (day 0) and the 7 subsequent nights 
(days 1–7) to report their child’s temperature. We used log-binomial regression to calculate 
adjusted relative risks (aRRs) and excess risk for fever on days 0 to 1, adjusted for age group, past 
influenza vaccination and simultaneous receipt of selected inactivated vaccines.
EXPOSURES—Receipt of TIV and/or PCV13.
MAIN OUTCOME(S) AND MEASURE(S)—Temperature of 38°C or higher on days 0 to 1 
after vaccination.
RESULTS—On days 0 to 1, children receiving TIV and PCV13 simultaneously had higher rates 
(37.6%) of fever (temperature ≥38°C) than those receiving TIV (7.5%; aRR, 2.69; 95% CI, 1.30–
5.60) or PCV13 (9.5%; aRR, 2.67; 95% CI, 1.25–5.66). The excess risk of fever after TIV and 
PCV13 was 20 and 23 per 100 vaccinations compared with TIV without PCV13 and PCV13 
without TIV, respectively. Fever rates for days 2 to 7 were similar across groups. For days 0 to 1, 
74.8% of the text messages were confirmed delivered; for another 9.0%, delivery status was 
unknown. Response rates were 95.1% and 90.9% for days 0 and 1 for confirmed delivered 
messages, respectively.
CONCLUSIONS AND RELEVANCE—Simultaneous TIV and PCV13 administration was 
associated with higher transient increased fever risk than administration of either vaccine without 
the other product. Text messaging to prospectively assess a specific vaccine adverse event has 
potential for enhancing prelicensure and postlicensure monitoring of adverse events after 
immunization and deserves further study.
TRIAL REGISTRATION—clinicaltrials.gov Identifier:
During the 2010–2011 influenza season, an epidemiologic study conducted in the Centers 
for Disease Control and Prevention–supported Vaccine Safety Datalink (VSD) found that 
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trivalent inactivated influenza vaccine (TIV) was associated with an increased risk of febrile 
seizure during the day of and 1 day after vaccination (days 0–1) in US children who were 6 
to 59 months old. Risk was highest among those 6 to 23 months old who received TIV and 
13-valent pneumococcal conjugate vaccine (PCV13) simultaneously.1,2 Fever rates were not 
assessed.
Fever after pediatric vaccination is relatively common and therefore more amenable to study 
than febrile seizure, which occurs in 2% to 5% of children.3 Furthermore, fever can lead to 
parental concern and health care visits.4 We sought to study rates of fever in children 
receiving the 2011–2012 TIV formulation (which was the same TIV formulation used in 
2010–2011)5,6 and PCV13. We hypothesized that fever rates would be significantly higher 
during days 0 to 1 after simultaneous vaccination with TIV and PCV13 compared with TIV 
or PCV13 without the other product.
In addition, we sought to use a novel method, text messaging, to assess postvaccination 
fever. Most US adults (91%) have cell phones.7 Latino adults are most likely to use text 
messaging.8 Although text messaging has been piloted for vaccine safety surveillance9,10 
and vaccination reminders,11–13 it has not been used to prospectively assess a specific 
vaccine safety question. We sought to assess the utility and acceptability of text messaging 
to monitor a vaccine adverse event. We hypothesized that parents would use text messaging 
to report postvaccination fever and report high satisfaction with its use.
Methods
We conducted a prospective observational cohort study during the 2011–2012 influenza 
season in 3 community-based clinics affiliated with New York–Presbyterian Hospital/
Columbia University Medical Center in New York City, serving a primarily Latino and 
publicly insured population. The clinics use a common electronic health record linked to a 
hospital immunization registry. All decisions regarding which vaccinations patients received 
were made by their health care professionals. It was not routine practice to provide 
antipyretics at vaccination.
Study Population
Families were eligible to enroll if they (1) had a child 6 to 23 months old receiving TIV 
and/or PCV13 from November 1, 2011, through April 5, 2012; (2) had a cell phone with the 
ability to receive text messages; and (3) spoke English or Spanish. Exclusion criteria 
included (1) child’s temperature of 38°C or higher at enrollment; (2) antipyretic 
administered within 6 hours before vaccination; (3) intent to use prophylactic antipyretics; 
(4) intent to move from New York City within 6 months; (5) child not with guardian; (6) 
parental inability to read text messages; or (7) child received TIV or PCV13 within 7 days 
before enrollment or live attenuated influenza vaccine on vaccination day. Receipt of other 
vaccines was permitted as was enrollment for more than one vaccination event.
Study Enrollment
Columbia University Medical Center’s institutional review board approved the study. After 
consent, families were verbally administered an intake form. Text messaging procedures 
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were explained. Parents were trained to use a temporal artery thermometer14 and were 
instructed to take the temperature when their child felt febrile or nightly if the child did not 
feel febrile. Participant compensation included the thermometer (retail price, $30-$35) and a 
round-trip New York City Transit Authority Metrocard ($4.50).
Follow-up
Families were sent interactive text messages nightly on days 0 to 7 and reported the highest 
temperature since the last text, time taken, antipyretic use, and, for those with fever, care 
sought. Messages were sent in English or Spanish based on participant preference. Study 
staff called parents not responding to text messages in full or in part. Starting in February 
2012, families were also given a card and a preaddressed stamped envelope to complete with 
the same information as the texts to add to reporting. Using a medical record abstraction 
tool, all health care visits after vaccination on days 0 to 7 were recorded from the electronic 
health record. From February through May 2012, families enrolled after January 1 were 
contacted to complete a telephone survey about satisfaction and future participation in 
vaccine safety studies.
Outcomes
The primary outcome was fever (temperature ≥38°C) on days 0 to 1 after vaccination. Main 
text messaging–related outcomes included response to delivered texts on days 0 to 1 and day 
7 and parental satisfaction (very satisfied, somewhat satisfied, somewhat dissatisfied, or very 
dissatisfied) with reporting by text messaging.
Statistical Analysis
Fever After Vaccination—Children were included in the primary fever analysis if they 
had a (1) valid temperature measurement (defined as temperature ≥35°C) reported on both 
day 0 and day 1 or (2) had a fever (temperature ≥38°C) reported on either day 0 or day 1 
even if the response was invalid or missing on the other day. We compared the presence of a 
temperature of 38°C or higher on days 0 to 1 using the Pearson χ2 test in children receiving 
TIV and PCV13 vs TIV without PCV13 or PCV13 without TIV. Children with and without 
antipyretic use were classified as having a fever based on the same cutoff values.
On the basis of fever in the first week of vaccination in prior studies of TIV (11%)15 and 
PCV13 (30%),16 with a total sample size of at least 461, we were powered to detect a 2-fold 
increase in fever rates comparing TIV and PCV13 vs TIV without PCV13 and a 1.7-fold 
increase vs PCV13 without TIV, assuming an 80% power and 5% type I error.
We also assessed associations between day 0 to 1 fever and potential covariates, including 
demographic factors (child age group, sex, and race/ethnicity), history (medical problem 
associated with high risk of influenza complications5 and reported family history of vaccine 
reaction), and enrollment month. Interaction between covariates and vaccine type (TIV and 
PCV13, TIV, or PCV13) was assessed at P < .05. Race/ethnicity was based on self-report by 
the caregiver. Pairwise correlation was tested via Pearson correlation coefficients, whereas 
multicollinearity was assessed using conditional indexes. We used log-binomial regression 
to calculate relative risks adjusted for the significant covariates at the level of P < .05 anda 
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priori selected covariates that could affect day0 to1 fever: age group (6–11 and 12–23 
months), history of prior influenza vaccination, and coadministration of common inactivated 
vaccines (combination diphtheria and tetanus toxoids and acellular pertussis, Haemophilus 
influenzae type b, and 4 inactivated poliovirus [DTaP-Hib-IPV], Hepatitis B and Hepatitis 
A) (eTable 1 in the Supplement). All 3 vaccination types (TIV and PCV13, TIV, and 
PCV13) were analyzed in the same model, with TIV and PCV13 as the referent, to allow 
creation of one model. Data are presented as the reciprocal value illustrating the risk of 
simultaneous vaccination vs vaccination of one product without the other. Using Mantel-
Haenszel standardized risk estimates, we also determined the risk difference (excess risk) by 
calculating the adjusted fever rate in children receiving TIV and PCV13 minus the rate in 
those receiving PCV13 or TIV without the other product. This analysis estimates the number 
of additional fevers seen per 100 children vaccinated simultaneously with TIV and PCV13.
Secondary analyses assessed differences for temperatures of 39°C or higher to determine 
relationships with moderate fever, as well as differences stratified by TIV dose: first (TIV-1) 
or second (TIV-2) that season. In addition fever rates on days 2 to 7 were assessed to verify 
the risk window of days 0 to 1. Children were included if they had a valid temperature 
measurement reported on all 6 days or reported fever.
Three sensitivity analyses were conducted. First, children with reported antipyretic use on 
days 0 to 1 were excluded. Second, data only for first enrollments was analyzed. Third, 
generalized estimation equations were used to account for the children with multiple 
enrollments.
Use of Text Messaging—The percentage of messages confirmed delivered and response 
rates on days 0 to 1 are described. Bivariate analyses assessed the association between 
demographic factors and response to delivered texts on days 0 to 1 and day 7. The 
percentages of participants who returned cards and parental satisfaction information are 
described.
Analyses were performed using SAS statistical software, version 9.3 (SAS Institute Inc) and 
SPSS statistical software, version 19 (SPSS Inc).
Results
Five hundred thirty of 614 eligible participants (86.3%) enrolled, representing 484 children. 
A total of 39.2% received TIV without PCV13, 20.8% PCV13 without TIV, and 40.0% 
simultaneous TIV and PCV13 (Figure 1). Children were primarily Latino and publicly 
insured; 54.2% were 6 to 11 months old (Table 1). Approximately half (56.2%) of caregivers 
had a high school education or less. Nearly all (95.2%) had unlimited text messaging plans 
and texted at least weekly (91.7%).
In adjusted analyses, children who received simultaneous TIV and PCV13 were 2.7 times 
more likely to have a day 0 to 1 temperature of 38°C or higher than those receiving TIV 
without PCV13; the same adjusted relative risk (aRR) was found vs PCV13 without TIV 
(Table 2; eTable 2 and eTable 3 in the Supplement). Significantly higher rates of temperature 
of 39°C or higher during days 0 to 1 after TIV and PCV13 were also observed vs TIV but 
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not vs PCV13 (Table 2). The adjusted risk difference for temperatures of 38°C or higher 
were 0.20 (95% CI, 0.06–0.35) for TIV and PCV13 vs TIV and 0.23 (95% CI, 0.11–0.34) vs 
PCV13, indicating an additional 20 cases of fever per 100 children vaccinated with TIV and 
PCV13 vs TIV and an additional 23 cases with TIV and PCV13 vs PCV13. The adjusted 
risk difference for temperatures of 39°C and higher for simultaneous TIV and PCV13 vs 
TIV was 0.15 (95% CI, 0.035–0.26).
Receipt of hepatitis B vaccine and previous receipt of influenza vaccine were correlated with 
each other (Pearson correlation coefficient, −0.79), yet there was no evidence of 
multicollinearity in our full model. No significant interaction was present between vaccine 
type and covariates for temperatures of 38°C or higher on days 0 to 1; interaction could not 
be assessed on days 0 to 1 for temperatures of 39°C or higher because of zero cell counts.
The aRR for fever was significantly higher after TIV-1 and PCV13 vs TIV-1 or PCV13 for 
temperatures of 38°C or higher but not for temperatures of 39°C or higher; no significant 
differences were observed for TIV-2 (Table 2). No between-group differences were found in 
fever rates on days 2 to 7 on bivariate or multivariable analyses for temperatures of 38°C or 
higher and 39°C or higher.
When children whose families reported antipyretic use on days 0 to 1 (n = 50) were 
excluded or when analyses were limited to first enrollments (n = 484), findings were similar. 
Generalized estimation equation models were similar to the original model assuming 
independent correlation except that the comparison of TIV-2 and PCV13 to TIV-2 became 
significant for temperatures of 38°C or higher (aRR, 2.22; 95% CI, 1.02–4.86). Of the 84 
children with a day 0 to 1 fever, 6 had a medical visit that included fever (3 after TIV and 
PCV13, 2 after TIV, and 1 after PCV13); 4 went to the emergency department and 2 to a 
primary care clinic. Four of the visits occurred on days 1 to 3. There were no 
hospitalizations or febrile seizures noted on days 0 to 7 for any study child.
Use of Text Messaging
On days 0 to 1, 74.8% of messages were confirmed delivered (773 of 1034 sent); for another 
9.0%, delivery status was unknown. For all days, 69.6% of messages were confirmed 
delivered; for 14.1%, delivery status was unknown. For families for whom delivery was 
confirmed, 95.1% replied on day 0; reply rates slowly decreased to 79.6% on day 7 (Figure 
2). Only caregiver age (day 7) and level of reported text message use at baseline before 
enrollment (days 0–1 and day 7) affected likeliness to respond to messages (Table 3).
For days 0 to 1 temperature data, 75.8% was via text, 8.7% via card, and 15.4% via 
telephone follow-up. Only 43.4% of those given cards returned them, and 39.1% returned 
cards with usable day 0 to 1 temperature data; on average, cards arrived on postvaccination 
day 19.
Among families completing the survey (325 of 418 [77.8%]), nearly all were very satisfied 
(84.9%), 12.9% were somewhat satisfied, and 94.1% were willing to re-enroll. Most either 
preferred text to paper reporting (65.7%) or had no preference (20.0%). Most (83.1%) 
indicated they would be willing to have their child’s blood drawn as part of a future study.
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Discussion
This study demonstrated that young children who received TIV and PCV13 simultaneously 
had an increased risk of fever in the day 0 to 1 postvaccination period compared with those 
who received TIV or PCV13 without the other product (with or without other vaccines). It 
also indicates the novel and potential use of text messaging to prospectively assess a vaccine 
safety question. Although this was the first postlicensure study in the United States to assess 
fever risk after simultaneous TIV and PCV13 administration, these findings are consistent 
with 2 observational studies conducted during the 2010–2011 season.2,17 Our study 
identified increased risk of fever after TIV and PCV13 on days 0 to 1 but not on days 2 to 7, 
validating the VSD findings of increased febrile seizure risk on days 0 to 1 in children 
receiving TIV and PCV13.2 Our findings using text message reporting were also similar to a 
TIV safety study17 using paper reporting in Canada, which found that children 6 to 59 
months old receiving TIV and PCV13 were more likely to have an axillary fever on days 0 
to 3 after vaccination than those receiving TIV without PCV13. Validation of these paper-
reported findings lends credibility to the use of text messaging as a method for surveillance 
and research of adverse events after immunization. This corroboration, along with high cell 
phone use and enrollment rates and minimal differences in response rates among 
demographic groups, also illustrates the potential utility of text messaging to enhance 
prelicensure and postlicensure monitoring of adverse events after immunization.
In our adjusted models, there were an additional 20 to 23 cases of temperature of 38°C or 
higher per 100 children with simultaneous vaccination vs TIV or PCV13 without the other 
product and 15 additional cases of temperature of 39°C or higher for TIV and PCV13 vs 
TIV. Our data suggest that simultaneous administration of TIV and PCV13 confers an 
overall transient higher risk of fever; however, this finding should be interpreted with caution 
because we did not assess the risk of fever in children receiving both TIV and PCV13 
simultaneously compared with receiving both vaccines but on different days. This risk 
should also be viewed in the context of overall benefits of both vaccines,5,18,19 the currently 
low influenza vaccination coverage,20 and the desire to decrease missed opportunities to 
vaccinate. Both in this study and the Canadian study,17 few medical visits resulted from 
fevers, supporting the Advisory Committee on Immunization Practices’ recommendation to 
administer TIV and PCV13 according to the routine schedule, including simultaneous 
vaccination.19 Health care professionals could use this information to provide anticipatory 
guidance for families regarding fever.21 Understanding this increased fever risk may be 
particularly useful in caring for children for whom postvaccination fever could be associated 
with increased morbidity, such as those with a febrile seizure history.22
The pathogenesis of higher fever rates associated with simultaneous administration of TIV 
and PCV13 is unclear. It is well known that bacterial and viral antigens provoke fever.23 
Therefore, the increased fever rate observed could be due to the increased antigen load of 
multiple vaccine epitopes. Alternatively, the balance between proinflammatory cytokines, 
such as interleukin 1, and the anti-inflammatory cytokines, such as interleukin 1 receptor 
antagonist and interleukin 10, could influence the degree of febrile response.24 It is possible 
that this specific vaccine combination results in higher levels of proinflammatory cytokines. 
A better understanding of the pathways that lead to fever is needed.25,26 To successfully 
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conduct such cytokine studies immediately after vaccination, near real-time reporting of 
fever and collection of biological specimens are needed. Unlike conventional methods for 
postlicensure surveillance and research of adverse events after immunization in which 
reporting may be delayed,27 text message data are received in near real time and in an 
electronic form available for immediate review, thereby making such rapid collection of 
specimens possible on a larger scale.
Text messaging could be an important additional component to the current US vaccine safety 
monitoring effort. Spontaneous reporting systems, such as the Vaccine Adverse Event 
Reporting System, are useful to identify safety signals but not to test vaccine safety 
hypotheses.28 Although large linked databases, such as those used in VSD, are robust for 
studying rare serious adverse events after immunization, they have limited ability to capture 
nonmedically attended events.29 Prospective clinical studies are well suited to assess adverse 
events after immunization that occur outside medical settings but often use paper-based data 
collection, which can be slow and time consuming. In addition to complementing these 
systems, text messaging allows for standardization of surveillance across wide geographical 
areas through centralized deployment and monitoring. Although Internet surveillance may 
be similar, text messages are sent to the person’s own telephone and response can take 
seconds. In addition, in lower-income populations that may generally be underrepresented in 
studies,30 cell phone use is more common than computer-based Internet use.8,31,32 Although 
identifying adverse events that do not require medical attention could help with the 
underreporting of adverse events after immunization,28 the increase in reports may detract 
from identifying more clinically important adverse events after immunization; however, this 
may be offset by identifying a patient-centered outcome important to families. In addition, 
the methods could be adjusted to specifically capture more serious outcomes that may 
otherwise not be reported. Rapid monitoring of vaccine safety is an important component of 
national and international pandemic influenza plans.33
This study had several limitations. Children were not randomized to which vaccine they 
received; their own health care practitioners made all vaccine decisions. Regardless, no 
baseline difference was found between groups other than age. Although trends for higher 
fever risk after TIV and PCV13 vaccination with TIV-1 and TIV-2 in a given season were 
noted, this study was not powered to adequately make that distinction. Similarly, the study 
was not powered to assess differences between children receiving different doses of PCV13. 
Although the study controlled for receipt of combination diphtheria and tetanus toxoids and 
acellular pertussis, Haemophilus influenzae type b, and 4 inactivated poliovirus (DTaP-Hib-
IPV), we were unable to assess the potential effect of other diphtheria and tetanus toxoids 
and acellular pertussis products. This study was conducted during a single influenza season, 
and influenza vaccine strains change year to year5; documenting fever patterns with different 
formulations may be helpful. This study took place in a primarily Latino, urban population 
and may not be representative of the general population. Text messaging behaviors could 
differ, and limited data suggest that race/ethnicity may affect fever risk after influenza 
vaccination.34 Older caregivers were slightly more likely to continue responding at day 7. 
Not all text messages were delivered; patients used their own cell phones, some of which 
routinely block messages from a 5-digit short code. Use of a 10-digit long code (normal 
telephone number) would likely increase delivery rates. In addition, some data were received 
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by card and telephone follow-up; inclusion of these adjunct methods when using text 
message collection may be helpful. Finally, the main outcome of the study was to assess 
fever rates, and we did not conduct a randomized trial comparing text message reporting and 
paper reporting. Future studies could directly compare these modalities for vaccine safety 
surveillance.
Conclusions
Simultaneous TIV and PCV13 administration was associated with a higher transient 
increased fever risk than administration of either vaccine without the other product. Future 
studies could address the potential benefits and risks of administering TIV and PCV13 on 
different days or the effect of prophylactic antipyretics on vaccine-specific immune 
responses35 in patients for whom fever should be avoided for medical reasons. In addition, 
the use of text messaging to prospectively assess a specific vaccine adverse event has 
potential for enhancing prelicensure and postlicensure monitoring of adverse events after 
immunization and deserves further study.
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Figure 1. Study Flow Diagram
In patients receiving TIV-1, 68% of TIV-1 doses are the first influenza dose the patient 
received in the 2011–2012 season but not necessarily the first dose that patient ever received. 
In patients receiving TIV-1 and PCV13, 96% of TIV-1 and PVC13 doses are the first 
influenza dose the patient ever received. In patients receiving PCV13, 0.9% were receiving 
their first dose, 2.7% their second dose, 16.4% their third dose, and 80.0% their fourth dose. 
In patients receiving TIV and PVC13, 0.9% were receiving their first dose of PCV13, 5.7% 
their second dose, 65.6% their third dose, and 35.8% at least their fourth dose. In patients 
receiving TIV-1 and PCV13, 1.3% were receiving their first dose of PCV13, 6.4% their 
second dose, 81.5% their third dose, and 10.8% their fourth dose. In patients receiving TIV-2 
and PCV13, 0% were receiving their first dose, 3.6% their second dose, 20.0% their third 
dose, and 76.3% at least their fourth dose. PCV13 indicates 13-valent pneumococcal 
conjugate vaccine; TIV, trivalent inactivated influenza vaccine; TIV-1, first influenza dose 
that season; and TIV-2, second influenza dose that season.
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Figure 2. Response Rates to TextMessages Monitoring for Fever on Day 0 Through Day 7
A, Response rates to all messages regardless of delivery status.
B, Response rates only to messages with confirmed delivery.
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